Pipeline

Back to overview

AMR research approaches

Combatting rising Anti-microbial resistance (AMR)

Continuous spread and rise of multi-drug resistant (MDR) bacteria leave clinicians with very limited
options to treat gram-negative infections, resulting in increasing morbidity and mortality. Strains
resistant to all antibiotics have recently emerged, recreating situations typical of the pre-antibiotic era
with no option left for treatment at all. This so-called “antibiotic resistance crisis” may become an
urgent problem in the near future if no new antibiotic classes (“game changers”) are introduced into
the market to break current resistance pattern. AiCuris’ highly innovative antibacterial pipeline
comprises several discovery programs at different stages, targeting multi-drug-resistant (MDR)
pathogens with novel and resistance-breaking classes of molecules. Public private partnerships and
close collaborations with leading organizations, institutions and scientists worldwide are the key to our
success.